SAN DIEGO--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) today announced that the Company is presenting study findings from its expanded pain management portfolio at the American Pain Society’s Annual Meeting. Leading researchers are presenting safety and efficacy data for ACUROX® and scientific data confirming validation of innovative measurement standards to evaluate the likeability of opioid analgesics, such as EMBEDA™. King is developing several novel opioid treatment options, including long-acting opioids EMBEDA™ and REMOXY®, and a short-acting opioid, ACUROX®, each of which is uniquely designed to deter misuse and abuse commonly associated with currently approved opioid analgesic products. New Drug Applications for ACUROX®, EMBEDA™ and REMOXY® are all currently under review by the U.S. Food and Drug Administration.
